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Abstract
Background: Optimising hearing and vision function may be important in improving a range of outcomes for
people living with dementia (PwD) and their companions. The SENSE-Cog cross-national randomised controlled trial
(RCT) is evaluating the effectiveness of a sensory intervention (SI) to improve quality of life for PwD with concurrent
hearing and/or vision impairment, in five European countries. To ascertain how or why the intervention will, or will
not, achieve its outcomes, we have designed a process evaluation to explore potential discrepancies between
expected and observed outcomes. This will also help us to understand how context may influence the outcomes.
Here we describe the protocol for this process evaluation, which is embedded within the RCT.
Methods/design: We will use a mixed methods approach with a theoretical framework derived from the UK
Medical Research Council’s’ guidance on process evaluations. It will include the following: (1) evaluating how key
aspects of the intervention will be delivered, which will be important to scale the intervention in real world
populations; (2) characterising the contextual issues, which may shape the delivery and the impact of the
intervention in different countries; and (3) investigating possible causal mechanisms through analyses of potential
moderators and mediators. To avoid bias, we will analyse the process data before the analysis of the main
effectiveness outcomes.
Discussion: This evaluation will provide insight into how the complex SENSE-Cog SI will be tailored, enacted and
received across the different European contexts, all of which have unique health and social care economies. The
findings will provide insight into the causal mechanisms effecting change, and will determine whether we should
implement the intervention, if effective, on a wider scale for PwD and concurrent sensory impairment.
Trial registration: ISRCTN, ISRCTN17056211. Registered on 19 February 2018.
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Background
There is growing evidence that people with dementia (PwD)
with ageing-related hearing and vision impairment experi-
ence worse outcomes compared to PwD with optimal sen-
sory function. These outcomes include increased
disorientation, difficulties self-locating using visual or audi-
tory cues, higher levels of distress leading to agitation and
aggression and increased prevalence of hallucinations, delu-
sions and depression [1–3]. Sensory impairment itself can
worsen cognitive decline, as well as exacerbate the social iso-
lation that is often associated with dementia [4]. Individuals
may withdraw from social activities and hobbies and be-
come marginalised [5–8]. Furthermore, burnout and phys-
ical exhaustion in care partners can be amplified by
communication barriers [3] and greater dependency of the
PwD. Thus, we designed the SENSE-Cog randomised con-
trolled trial (RCT) to answer the research question, ‘Can a
home-based, tailored ‘sensory intervention’ (SI) improve
quality of life in PwD with comorbid hearing and/or visual
impairment?’
The multi-component SI that the SENSE-Cog trial will
evaluate comprises assessment, treatment and support of
hearing and vision impairment in PwD. We developed
the SI iteratively over 24 months. This involved: (1) a
scoping review of the literature [9]; (2) an in-depth
qualitative exploration of the support care needs of PwD
with sensory impairment in three European countries
[10]; (3) an international survey (n = 653); and (4) an
interdisciplinary Expert Reference Group (n = 17) [11,
12]. The findings were synthesized into a draft SI that
was then field tested in the UK, France and Cyprus [13–
15], prior to development of the protocol for the full
multi-site RCT [16], the SENSE-Cog trial.
The SENSE-Cog trial is a 36-week parallel-group,
observer-blind, multicentre, superiority RCT comparing
the individualised SI to usual care in PwD with hearing
and/or visual impairment and their companion (the par-
ticipant ‘dyad’). Briefly, it involves 354 randomized dyads
(1:1; 177 per arm) in five European sites: Athens
(Greece), Dublin (Ireland), Manchester (UK), Nice
(France), and Nicosia (Cyprus). The primary outcome of
the trial is quality of life in the PwD, measured at 36
weeks post-baseline using the DEMQOL [17]. The
DEMQOL is a 29-item, interviewer-administered, self-
report questionnaire with good psychometric properties
in persons with mild to moderate dementia. Second-
ary outcomes include neuropsychiatric symptoms,
measures of mental wellbeing, sensory and cognitive
functional ability, relationships and health resource
utilisation. Companion outcomes and health economic
measures are also being assessed. Here we describe
the protocol for a process evaluation of the RCT as
per the UK Medical Research Council (MRC) recom-
mendations [18].
‘Complex interventions’, such as the SENSE-Cog SI,
are defined as those comprising multiple components
interacting to produce change [18, 19]. The range of
outcomes, and the degree of tailoring or flexibility re-
quired for each individual participant, is significant, thus
adding to the complexity [12]. While RCTs are the
soundest means of inferring causality of an intervention,
they cannot ascertain how or why an intervention may
or may not achieve the outcomes [20]. Thus, we have
embedded a detailed process evaluation within the RCT
to clarify this [18]. This evaluation, together with the
outcomes of the RCT, will enable policy makers, funders
and practitioners to determine whether the intervention
is effective or not, and whether it should be imple-
mented on a wider scale. This is particularly relevant for
the cross-national SENSE-Cog trial, which is taking
place in five European contexts. It will fill a significant
evidence gap in the management of hearing and vision
impairment in PwD.
The specific aims of this process evaluation are to: (1)
explore the delivery, or the process through which the SI
will be offered, including barriers and facilitators; (2)
evaluate contextual issues and clarify factors that may
affect the SI delivery, mechanisms and outcomes [21];
and (3) investigate possible causal mechanisms, using
analyses of potential moderators and mediators.
Methods/design
The protocol for our process evaluation follows a sys-
tematic approach for the design and conduct of the
evaluation [18].
Planning the process evaluation
Working with intervention developers and implementers
A process evaluation requires a degree of independence
to appraise the intervention team’s delivery of the trial
[18]. Thus, we delegated oversight of the evaluation to
an expert not involved in the day-to-day conduct of the
RCT but on the wider SENSE-Cog team (CA). Regular
process evaluation reports will be made at Trial Steering
Committee meetings [16] and specific meetings with the
study chief investigator (IL), the methodologist (EF) and
the process lead (CA).
Overlap of the process and outcomes and cost-effectiveness
evaluations
Due to the complexity of the study, we have embedded
the process evaluation within the daily conduct of the
outcomes and cost-effectiveness evaluations. Thus, data
for all three purposes are being collected concurrently,
and some measures may be used for both process and
outcome evaluations. During team training, we empha-
sized the multi-purposing of data and the need to main-
tain ‘researcher equipoise’.
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Description of the intervention
We have previously detailed the SI components and im-
plementation [12]. In summary, the SI, which is deliv-
ered as a ten-session programme by a trained ‘sensory
support therapist’ (SST) and audiologists/optometrists, is
outlined in Fig. 1. It involves several components, not-
ably: (1) identifying and correcting any vision or hearing
impairment; (2) supporting adherence to the hearing
and/or vision devices, through advice and training in
correct use and care; (3) enhancing communication be-
tween the PwD and their companion; (4) demonstrating
environmental aids and sensory devices; and (5) acces-
sing relevant support services and social networks. The
non-intervention group receives ‘care as usual’ (CAU)
access to the services and interventions normally avail-
able to PwD and their companions in their respective
countries and sites.
Causal assumptions about how change will be produced
To understand fully the impact of the intervention on
the outcomes, and to generalise the findings in the pan-
European context of SENSE-Cog, an exploration of
causal mechanisms and unanticipated pathways is
needed [19]. We will do this by extracting pre-specified
mediating variables and qualitative data (from a sub-
sample of 30 participant dyads) and evaluating adverse
events and unexpected consequences of the intervention.
We will also undertake semi-structured interviews with
the SSTs at each of the five study sites.
The principal aim of the intervention is to improve
quality of life and functional ability by improving sensory
function through devices and behavioural change.
Dementia-related quality of life comprises the domains
of daily activities (activities of daily living and self-care),
physical health and wellbeing, cognitive functioning and
Fig. 1 How the elements of the ‘COM-B Behaviour Change’ model and components of the sensory intervention link together. BADLs Bristol
Activities of Daily Living Scale [22], Bangor The Bangor Goal-Setting interview [23], DEMQoL Dementia Quality of Life [24], FCS Family Caregiving
Role Scale [25], HADS Hospital Anxiety and Depression Scale [26], HASK Hearing Aid Skills and Knowledge test [27], HHIE-25 Hearing Handicap
Inventory for the Elderly [28], GHQ-12 General Health Questionnaire [29], MoCA Montreal Cognitive Assessment [30], NPI-12 Neuropsychiatric
Inventory [31], RSS Relationship Satisfaction Scale [32], SF-12 Short Form Health Survey [33], VA LV-VFQ-20 Veterans Affairs Low vision Visual
Functioning Questionnaire [34]
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social relationships [35]. To influence these domains, we
have adopted the COM-B component of the Behaviour
Change Wheel [36] as our framework for how the inter-
vention might work. According to this model, behav-
ioural change (‘B’) results from: capability (‘C’), the
individual’s psychological and physical capacity to en-
gage in the activity concerned; opportunity (‘O’), the ex-
ternal factors that support behavioural change; and
motivation (‘M’), the conscious and sub-conscious pro-
cesses that direct decision making [36]. In Table 1 and
Fig. 1, using a logic model, we outline how each COM-B
element aligns with specific components of the SI, and
how these might hypothetically lead to improvements in
quality of life, our primary outcome.
Briefly, for capability, the sensory aids (i.e. hearing
aids, glasses and sensory environment modification in
the home) and SST adherence support will improve
hearing and vision (physical capability), which will
enhance sensory-cognitive function and overall func-
tional ability and reduce neuropsychiatric symptoms
[37–41]. The SST will train communication skills and
improve knowledge of dementia and sensory impairment
(psychological capability). This will increase opportunity
by decreasing dependency on companions, enhancing
social interactions and reducing loneliness. Adherence
support for PwD with sensory devices will enhance hear-
ing [42], vision [43] or both [15]. Furthermore, social op-
portunities will be enhanced through signposting outside
the home, thus addressing social isolation, improving so-
cial relationships and providing respite for companions.
Regarding motivation, higher sensory-cognitive function
and improved neuropsychiatric symptoms will improve
self-efficacy, self-esteem and mental wellbeing [44, 45].
However, motivation may be reduced in dementia, par-
ticularly if apathy is present. Thus, the SI will address
this through goal setting. We will measure apathy to
Table 1 Theoretical basis and logic model for how the sensory intervention may impact the person with dementia
Theoretical COM-B domain Component of the sensory
intervention
Behaviour change (B)
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Correct visual / auditory
impairment
• Hear and see better
(HHIE-25;VA-LVVFQ-20)





























• Reduced apathy (NPI-
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• Appropriate levels of
support from
companion
Referral to health and social
care services
• Uptake of health and
social care services










(in dementia, apathy and
loss of motivation is













BADLs Bristol Activities of Daily Living Scale [22], DEMQoL Dementia Quality of Life [24], FCS Family Caregiving Role Scale [25], HADS Hospital Anxiety and
Depression Scale [26], HASK Hearing Aid Skills and Knowledge Test [27], HHIE-25 Hearing Handicap Inventory for the Elderly [28], GHQ-12 General Health
Questionnaire [29], MoCA Montreal Cognitive Assessment [30], NPI-12 Neuropsychiatric Inventory [31], RSS Relationship Satisfaction Scale [32], SF-12 Short Form
Health Survey [33], VA LV-VFQ-20 Veterans Affairs Low vision Visual Functioning Questionnaire [34]
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take account of motivation as a potential moderator, or
even mediator, of the intervention’s impact. Greater in-
dependence and communication ability in the PwD will
reduce companions’ burden and stress, which will also
impact positively the overall wellbeing. Attitudes and
knowledge training will support change maintenance
and relationship quality [46].
Identification of key uncertainties and developing a
framework for the process evaluation
In Table 2, we identified key uncertainties to address for
each SI. We will use a mixed method approach to cap-
ture the data for the evaluation. This will involve a var-
iety of instruments, as outlined in Table 3.
Exploration of delivery
To ascertain whether the SI is delivered (i.e. ‘how’) and
enacted (i.e. ‘what’) as intended [18], we will examine the
fidelity and dose (i.e. duration, number and frequency of
SI visits) of the delivered intervention. Due to potential
burden on participants, we have chosen not to include an
external evaluation of fidelity (i.e. independent observer
during sessions). Instead, we will rely on the proxy meas-
ure of ‘fidelity’ as determined by thoroughness of SST
training and supervision, use of therapist manual and SST
logbook recordings of sessions. We will document the na-
ture of the support offered by the intervention, including
the type of corrective devices, the environmental changes
to support sensory function, the number and types of re-
ferral or signposts to extra-trial services. These data will
be captured through participant diaries (the PwD and
their companion) and the SST logbook.
Specifically, the PwD diaries will contain Likert style
ratings [50] of acceptability and tolerability of SI visits,
including measures of helpfulness, effort, fatigue, under-
standing and motivation; and how acceptable the cor-
rective sensory devices are. The companions´ diaries will
capture data relating to how the PwD engages with the
visit, how the PwD is adapting to their sensory aids, and
how confident the companion feels in supporting the
PwD in using the aids. The SST logbooks will contain de-
tails of each visit, the components of the SI delivered,
participant response to the intervention and skill in
managing their aids. Additionally, the SST logbooks will
detail how the SI is specifically tailored to the dyad.
We will assess reach through the representativeness of
the sites, the recruitment process (refusal rate, attrition
rate) and the representativeness of the study population
according to the target population [51].
Evaluation of contextual issues
The SENSE-Cog RCT will take place in several different
countries and involve three languages (English, French and
Greek). Thus, contextual issues, which are external to the
intervention itself, need to be carefully considered. These
include differences in language, culture, access to services
and the health and social care economy. Context may influ-
ence the SST’s ability to foster change in the participant
dyad’s circumstances. For example, for social isolation, the
SST may recommend attendance at a local lunch club;
however, if transportation is not suitable for individuals
with sensory and cognitive impairment, the opportunity to
take up the offer will be hampered. Likewise, communica-
tion training with companions may be differently received
in diverse cultural and linguistic contexts. Thus, the same
intervention may have divergent outcomes according to the
setting in which it is delivered [18]. The dyadic relationship
(between the PwD and their companion) should also be
considered because the level of support and quality of rela-
tionship may vary among dyads. To capture contextual
data, we will collect information from the demographic and
outcome measures, the participant dyad diaries, the SST
logbook and in-depth qualitative interviews of a sub-sample
Table 2 Identifying key uncertainties to address in the process evaluation for each component of the sensory support intervention
Sensory support intervention component Key uncertainty to address
Correct visual/auditory impairment Is vision/hearing impairment actually corrected?
Training in correct use of hearing aid/glasses How well are the devices used by the PwD?
Communication training Is the companion utilising the techniques?
Home-based functional assessment What are the types and extent of functional
impairment identified by the sensory support therapist?
Referral to health and social care services What types of services are available at each site?
How many referrals were made and actioned?
Provision of supplementary sensory devices
in the home environment
How many of these were supplied and how often
and effectively were they used?
Referral to social/hobby/interest activities How many referrals were made and actioned?
Individualised goal setting What is the number and types of goals set with the participant?
How many goals were achieved?
What is the level of apathy present (ascertained only after
final assessment data collected?
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Table 3 Measurement instruments used to collect quantitative and qualitative data to inform the process evaluation
Measurement tool Data captured by
whom? About
whom/what?
Timing of data capture Process evaluation (Capability ´C´, Opportunity ´O´, Motivation





Screening To assess characteristics of companion and
participant (covariates of age, gender, living
conditions influencing outcomes)
1b) Medical history Researcher about
dyad
Screening Dementia sub-type and medication may
influence uptake and effectiveness of intervention
(eliciting the type of memory impairment and
the current medication)
1c) HearCheck




Screening To establish the baseline for ‘C’ and ‘O’ for
intervention/optimisation of function (screening
for severity of visual and hearing loss of participant)
1d) MoCA Researcher about
PwD
Screening To ascertain impact of sensory optimisation on cognitive
ability as intermediate step (‘C’ and ‘M’) leading to improved
QoL (assessing cognitive level of participant scale (score≥ 10);
also decides whether the participant is appropriate
candidate for the study)
1e) DEMQoL Researcher about
PwD
Baseline The primary outcome of the behavioural change process,
resulting from intermediate impacts (assessing quality
of life of PwD by addressing all parts of the process
evaluation: ´C´, ´O´, ´M´)
1f) BADLs Companion about
PwD
Baseline To ascertain impact of sensory optimisation on functional
ability as intermediate step (‘C’ and ‘M’) leading to improved
QoL (assessing functional ability of PwD)
1g) VA LV-VFQ-20 Researcher about
PwD and
companion
Baseline Improvement in sensory input affects ‘C’, ‘O’ and ‘M’, all
impacting on intermediate outcomes leading to overall








1i) NPI-12 Researcher and
companion about
PwD
Baseline To ascertain impact of sensory optimisation on
neuropsychiatric function as intermediate step
(‘C’, ‘O’ and ‘M’) leading to improved QoL
(assessing behavioural and psychological
symptoms like anxiety, agitation etc.)




Baseline, week 18, week
36
Improved dyadic relationship optimises ‘O’,
thus leading to improved QoL (capturing current
level of relationship satisfaction between the PwD
and study companion, reduce feelings of loneliness)
1
k)
EQ-5D-5 L Researcher about
PwD and
companion
Baseline To measure uptake of health services, enhancing ‘O’
(assessing health resource utilisation and capturing
the amount and type of support that is in place)
1 l) RUD-Lite Researcher and
companion about
PwD









Following randomisation To establish the baseline for ‘C’ and ‘O’ (assessing the
degree of the PwD’s visual and/or hearing loss)





To ascertain the ‘dose’ of the intervention (capturing the
number and type of corrective sensory devices
prescribed by the optometrist and/or audiologist)
3a) PwD diary (acceptability and
tolerability of therapy)




To ascertain the utility of the ‘correction’ component
of the intervention from the PwD’s perspective
(capturing the PwD’s ratings on acceptability
and tolerability of the SI and acceptability across
five indices (helpfulness, fatigue, effort, understanding
and motivation) as well as the PwD’s view about their
corrective sensory devices—also informing ´C´)
3b) PwD diary (acceptance of
devices)










To ascertain the utility of the ‘correction’ component
of the intervention from the companion’s perspective
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Table 3 Measurement instruments used to collect quantitative and qualitative data to inform the process evaluation (Continued)
Measurement tool Data captured by
whom? About
whom/what?
Timing of data capture Process evaluation (Capability ´C´, Opportunity ´O´, Motivation
´M´) and measurement instruments (details)
experiences (capturing companions’ ratings on the PwD’s response
to the session across five indices of therapy acceptability
(interest, autonomy, motivation, emotional responses
and mastery) recorded after each session)







To ascertain uptake/adherence with the corrective
devices; to assess level of inter-site variability
(capturing companions’ ratings on the PwD’s









To capture the companion training component
of the intervention; to assess level of inter-site
variability (capturing companion’s confidence
in supporting the PwD’s use of their corrective
sensory devices)




To ascertain dose of the intervention; to assess
level of inter-site variability by:
- Measuring the dose of the SI (number of
sessions, duration of each session and frequency)
- Quantifying the PwD’s capability, opportunity and
motivation to use their glasses/hearing aids
-Capture adherence to the protocol, i.e. which
aspects of the SI were delivered by the SST






4c) SST logbook (delivered
components record)










To measure little changes within ´M´ (capturing the
number and type of goals set by the PwD, and their
progress towards these during the SI—address
support care needs)








at end of sensory
intervention
To enhance self-efficacy both in PwD and companion:
´C´ and ´O´ (capturing the change in the PwD and
companion’s skills and knowledge in using their
corrective sensory devices through receiving the SI)
4f) GHABP By audiologist and
therapist about PwD
At audiology assessment
and at end of sensory
intervention
To ascertain improved dyadic communication outcomes:
´C´(capturing self-reported gains from
hearing aid use)





Intervention end To ascertain how the interviews with the dyads
were experienced (reflecting upon the positive
and negative experiences of intervention for
the dyads, perceived benefits/short-comings,
suggestions for improvement)
6) Battery of outcome measures By researcher about
PwD
Baseline, week 18, week
36
The secondary outcome of the support
intervention focusing on behavioural changes
(assessing outcomes for participants and
companions)





Prior to and post-SST
training
To assess level of inter-site variability as to
the SST by:
- A 13-item self-rated questionnaire to
identify existing knowledge and skills
necessary for the SST role and training
needs pre and post-SST training)
- Verifying that the SST has received training
in the delivery of the SI components)
- Verify that the SST is competent to undertake
the role
- Capturing the number, duration and essence of
supervision provided by the senior SST
- Assessing positive and negative aspects of
intervention, emerging adaptations, suggestions
for improvement


















MoCA Montreal Cognitive Assessment [30], DEMQoL Dementia Quality of Life [24], BADLs Bristol Activities of Daily Living Scale [22], VA LV-VFQ-20 Veterans Affairs
Low vision Visual Functioning Questionnaire-20 items [34], HHIE-25 Hearing Handicap Inventory for the Elderly-25 items [28], NPI-12 Neuropsychiatric Inventory-12
items [31], RSS Relationship Satisfaction Scale [32], EQ-5D-5 L 5-level EuroQol 5-dimension [47], RUD-Lite Resource Utilization in Dementia-Lite [48], GHABP Glasgow
Hearing Aid Benefit Profile [49]
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Table 4 Participant assessment and follow-up visit schedule for the SENSE-Cog Trial
0Baseline, follow-up and end visits may be split into two visits, occurring within a maximum of a 2-week window according to the PwD’s needs
1Clinical examination including assessment of vision impairment (using the PEEK tool), hearing impairment (using the HearCheck device), level of cognitive
impairment and other eligibility criteria and medical diagnostic of depression
2 Baseline (except for the MoCA scale, which will be performed at screening), W18 and W36 (around 2 to 2.5 h)
3The number of sessions may vary from participant to participant but the maximum number of visits will be ten at an average rate of one per week. The order
and duration of each component may vary according to the participants’ needs, as determined in collaboration with the researcher, the PwD and the companion
The remaining weeks until week 18 will allow the SST to revisit and recap previous components, based on the participant’s individual needs and goal attainment
4In case of dual impairment, the hearing assessment will be done first, followed by the vision assessment, if possible
5A qualitative interview will be consecutively proposed to each dyad:
- Who experienced completed SI (all intervention visits scheduled by the SST, in addition to the full hearing and vision assessments)
- at the therapist discretion based on their clinical impression of the person be able to provide meaningful feedback
- and who are willing to
- until we reach participation of 60 people (30 interviews), six dyads per site: four dyads with single impairment (two hearing only and two vision only if possible)
and two dyads with dual impairment
This qualitative interview will take place within 2 weeks of SI completion. One additional interview, if possible, will be undertaken with a dyad which did not
complete the full SI
W week
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of participant dyads (n = 30 dyads across the sites), as de-
tailed in the SENSE-Cog trial protocol [16].
Sampling and timing of data collection
We will collect characteristics of each participant dyad,
including gender, age and support structure at the
screening visit, and at baseline, week 18 and week 36
(Tables 3 and 4). Following each SI visit (for the active
arm), participant diaries and SST logbooks will be com-
pleted. The sub-sample qualitative interviews will take
place within 2 weeks following the SI (details described
in [16]). Training logs for the SSTs were collected prior
to study start. SST supervision logs and fidelity checks
of the SST logbooks are being collected throughout the
trial. SST interviews will be held within 2 weeks after the
last intervention visit of the last randomised dyad in
each site. Briefly, these interviews will explore the ex-
perience of having received the intervention, from the
perspective of each member of the dyad. The sample size
for this sub-sample was selected to achieve theoretical
and data saturation. The interviews from all sites will be
analysed by using conventional qualitative content ana-
lysis [52] and a grounded theory approach [53].
Analysis
To avoid biased interpretation, as recommended by the
MRC’s guidance, we will analyse and explore process
data arising from the qualitative interviews and context-
ual factors before the unblinded trial outcomes are
known [18]. We will use the process data to generate
specific hypotheses (pre-trial explanation before trial
outcomes are revealed) regarding factors that moderate
and/or mediate the effect of the SI on outcomes, notably
quality of life. This will minimise the risk of ‘fishing’ for
relationships and falsely significant findings due to mul-
tiple testing.
Moderator analyses will be undertaken, with appropri-
ate caution, to investigate any influence of the baseline
characteristics of the dyads (e.g. age, gender, type of sen-
sory impairment, level of cognitive impairment, type of
companion) and country/site effect on the strength and/
or direction of the relationship between the SI and the
outcomes. We will undertake mediation analyses to as-
sess the degree to which the impact of the SI on the
stated outcomes is a direct effect, or is indirect via the
hypothesised mediating factors which will be modelled
as latent variables in a structural equation modelling
framework.
We will conduct the moderator/mediator analysis only
after the final RCT analysis has been completed and the
dataset has been un-blinded. We will do this regardless
of whether the SI has a significant direct impact on the
primary outcome.
We will apply a regression framework, using newer
methods and statistical models [54, 55] that improve on
traditional approaches (e.g. [56]). These models can be-
come complex, particularly when controlling for mul-
tiple covariates. Thus, depending upon the number and
complexity of the hypotheses to be tested, we will assess
whether it will be better to analyse each factor separ-
ately, or to combine sets of moderators and/or mediators
into a ‘conditional process analysis’ [54]. We will con-
duct separate analyses for those variables available in
both trial arms, and those available in the intervention
group only (e.g. related to the SI). The latter analyses
will help to identify process measures that are part of
the SI and may moderate its efficacy (for e.g., number of
SST visits, SST experience and fidelity), using appropri-
ate techniques [57].
Discussion
The process evaluation of the SENSE-Cog RCT will ap-
praise several important aspects of the delivery of the
intervention, the context of delivery and the hypothe-
sised causative mechanisms. These issues are key to
interpreting the effectiveness outcomes of the trial and,
if outcomes are positive, to assist in understanding im-
plications for scale-up in clinical settings. The SI will
have multiple interacting components: assessing and
correcting hearing and vision impairment (hearing aids
and/or glasses lenses), training in the use of the devices,
enhancing communication within the dyad, optimising
the home sensory environment and supporting engage-
ment in health and wellbeing opportunities in the com-
munity, including social integration and external support
services.
A key challenge in delivering the SENSE-Cog SI is to
maintain standardisation and rigour when implementing
such a complex intervention across five different Euro-
pean sites. The SENSE-Cog SI is ambitious in its vision
in addressing three co-morbidities simultaneously—cog-
nitive impairment, hearing loss and vision loss—and to
assess the impact of a psychosocial intervention on man-
aging these impairments. We will aim to capture the cul-
tural, social and economic nuances of the respective
European study sites whilst deriving results that can be
applied in a pan-European context. To ensure that we
capture the cultural differences from the qualitative in-
terviews, we will keep translation to a minimum, as rec-
ommended by Haak et al. [58].
The theoretical model with causal relationships will be
informed by the mediation analyses. The elicited data
will also enable us to ‘test’ the theoretical model of the
COM-B by addressing the key uncertainties listed in
Table 1. This will be the first opportunity to evaluate
empirically the COM-B model in a RCT setting, as dem-
onstrated in Fig. 1.
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Strengths and limitations of the study
A strength of our study protocol includes the use of a
mixed method approach, including both qualitative and
quantitative measures, to carefully explore the ‘how and
why’ of the intervention. Another strength of our ap-
proach includes the sound theoretical framework on
which the intervention was developed, and the iterative
manner in which it was modified and field-tested [12,
15] before arriving at the final version of the interven-
tion, ready for full scale effectiveness testing. A limita-
tion (although also a potential strength) is the significant
degree of variability in the study sites due to the differ-
ent EU contexts in which the programme takes place, as
well as the variability of the intervention offered to each
participant dyad, resulting from the tailored approach.
Reporting and dissemination
We will report the results of the process evaluation de-
scribed here using a combination of reporting guidance,
including CONSORT [59] and COREQ (for the qualita-
tive outcomes) [60] as well as statistical methods for me-
diators and moderators [61]. We will submit the
findings to an open-access journal, as per the require-
ments of the funder. As recommended by others [51],
we have described our protocol in advance to foster
transparency in reporting and to help the development
and evaluation of complex psychosocial interventions for
PwD, an emerging area of health services research. Fi-
nally, we will link our outputs related to the SENSE-Cog
trial through the SENSE-Cog programme website (www.
sense-cog.eu).
Ethics approval and consent to participate
In Manchester, the study received final approval (version
3.0) by the NW Haydock ethics committee on 22 Janu-
ary 2018 and obtained sponsor approval on 8 March
2019. In Nicosia, the study received favourable opinion
on 27 September 2016 from the Cyprus National Bioeth-
ics Committee. In Athens, the Local Ethics Committee
of Health Sciences and Scientific Committee of the Egi-
nition Hospital of the National and Kapodistrian Univer-
sity of Athens ethics committee granted a favourable
opinion on 24 January 2018. In Dublin, the Saint James
Hospital/AMNCH Research Ethics Committee gave ap-
proval on the 25 October 2018. In Nice, the “Comité de
Protection des personnes Sud Est I” gave a favourable
opinion on 12 July 2018. Written consent is collected
from the participants eligible for the study, using proce-
dures in accordance with the national guidance regard-
ing informed consent and clinical research (for
individuals with or without capacity to consent) in each
of the participating countries (detailed in Regan
et al. [16]). All researchers have been fully trained in
Good Clinical Practice (GCP) and mental capacity
assessment skills and follow national guidance in their
respective countries, such as the Mental Capacity Act
(2005) in the UK. If a person lacks capacity, a nominated
consultee will be asked to deem whether it is in the
PwD’s best interests to participate.
Trial status
This process evaluation is based on the SENSE-Cog
RCT protocol version 4.0 of 16 November 2018. The
overall SENSE-Cog research programme started in Janu-
ary 2016 and the SENSE-Cog RCT (Work Package 3.2)
started recruitment in summer 2018. Recruitment is ex-
pected to end in December 2020. The first qualitative in-
terviews with participants took place in November 2018.
The process evaluation will start in following the last
W36 assessment of the first randomized participant
dyad.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4135-4.
Additional file 1. Good Reporting of A Mixed Methods Study
(GRAMMS).
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